Huntington’s Disease Studies
We offer a comprehensive portfolio of validated in vitro and ex vivo cell based assays. These in vitro assays were developed specifically to screen RNAi and small molecules to novel mHTT regulators, identify small molecules for target degradation, optimize selective CNS penetrant ATM inhibitors, and other strategic therapeutic MOA’s.
Stem Cell-Derived Striatal Neurons for In Vivo Huntington’s Disease Studies
Mariangela Iovino, PhD, Group Leader of Integrated Biology at Charles River presents at Neuroscience Day 2020 and takes a deep dive in to current Huntington’s disease research with stem cell-derived striatal neurons. View additional Neuroscience Day 2020 presentations here.
Huntingtin Detection Assay Using MSD Assay Platform
These in vitro assays were developed using the Meso Scale Discovery (MSD) technology. This technology allows for the quantification of HTT in many forms; full length, fragmented and aggregated HTT, from various species and against a variety of capture/detection antibodies.
HD Biomarker Detection
Our in vitro assays for the ultrasensitive detection of HD Biomarkers can be obtained using the Quanterix Simoa HD-1 platform. Assays have been validated to detect HTT levels using capture antibodies and Human Neurofiliment-Light(NfL) as an HD marker.